Epigenetic disregulation in oral cancer

International Journal of Molecular Sciences

Volumn 13, Issue 2, 2012, Pages 2331-2353

  Mascolo, Massimo ^a   Siano, Maria ^a   Ilardi, Gennaro ^a   Russo, Daniela ^a   Merolla, Francesco ^a   de Rosa, Gaetano ^a,b   Staibano, Stefania ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b REFERRAL CANCER CENTER OF BASILICATA   (Italy)

Author keywords

Epigenetics; Molecular therapy; Oral cancer; Prognosis; Tumor progression

Indexed keywords

DNA; MICRORNA; MICRORNAS;

6 METHYLGUANINE DNA METHYLTRANSFERASE GENE; CANCER GENETICS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CARCINOGENESIS; CDKN2A GENE; CHROMATIN; DEATH ASSOCIATED PROTEIN KINASE 1 GENE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DNA METHYLATION; DOWN REGULATION; E CADHERIN GENE; EARLY DIAGNOSIS; EPIGENETICS; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HIGH RISK POPULATION; HISTONE MODIFICATION; HUMAN; MALIGNANT TRANSFORMATION; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; MOUTH CANCER; N CADHERIN GENE; ONCOGENE; PHOSPHATASE AND TENSIN HOMOLOG DELETED ON CHROMOSOME 10 GENE; RAS ASSOCIATION FAMILY 1 GENE; RAS ASSOCIATION FAMILY 2 GENE; RELIABILITY; RETINOIC ACID RECEPTOR B2 GENE; REVIEW; RISK ASSESSMENT; RISK FACTOR; TRANSLATION REGULATION; TUMOR SUPPRESSOR GENE; UPREGULATION; VIROGENESIS; WART VIRUS; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN ASSEMBLY AND DISASSEMBLY; DISEASE PROGRESSION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETICS; HUMANS; MOUTH NEOPLASMS; PHYSIOLOGY; PROGNOSIS;

CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN ASSEMBLY AND DISASSEMBLY; DISEASE PROGRESSION; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MOUTH NEOPLASMS; PROGNOSIS;

EID: 84857660724     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms13022331     Document Type: Review

References (156)

1. Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55, 74-108.
2. Argiris, A.; Karamouzis, M.V.; Raben, D.; Ferris, R.L. Head and neck cancer. Lancet 2008, 371, 1695-1709.
3. Stewart, B.W.; Greim, H.; Shuker, D.; Kauppinen, T. Defence of IARC monographs. Lancet 2003, 361, doi:10.1016/S0140-6736(03)13003-6.
4. Mydlarz, W.K.; Hennessey, P.T.; Califano, J.A. Advances and perspectives in the molecular diagnosis of head and neck cancer. Expert Opin. Med. Diagn. 2010, 4, 53-65.
5. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M.J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58, 71-96.
6. Blot, W.J.; McLaughlin, J.K.; Winn, D.M.; Austin, D.F.; Greenberg, R.S.; Preston-Martin, S.; Bernstein, L.; Schoenberg, J.B.; Stemhagen, A.; Fraumeni, J.F., Jr. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. 1988, 48, 3282-3287.
7. Gillison, M.L.; Koch, W.M.; Capone, R.B.; Spafford, M.; Westra, W.H.; Wu, L.; Zahurak, M.L.; Daniel, R.W.; Viglione, M.; Symer, D.E.; Shah, K.V.; Sidransky, D. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J. Natl. Cancer Inst. 2000, 92, 709-720.
8. Gillison, M.L.; D'Souza, G.; Westra, W.; Sugar, E.; Xiao, W.; Begum, S.; Viscidi, R. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J. Natl. Cancer Inst. 2008, 100, 407-420.
9. N.F. Prognostic value of human papillomavirus in the survival of head and neck cancer patients: An overview of the evidence. Oncol. Rep. 2005, 14, 1239-1247.
10. Chaturvedi, A.K.; Engels, E.A.; Anderson, W.F.; Gillison, M.L. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J. Clin. Oncol. 2008, 26, 612-619.
11. Fakhry, C.; Westra, W.H.; Li, S.; Cmelak, A.; Ridge, J.A.; Pinto, H.; Forastiere, A.; Gillison, M.L. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J. Natl. Cancer Inst. 2008, 100, 261-269.
12. Lingen, M.W.; Pinto, A.; Mendes, R.A.; Franchini, R.; Czerninski, R.; Tilakaratne, W.M.; Partridge, M.; Peterson, D.E.; Woo, S.B. Genetics/epigenetics of oral premalignancy: Current status and future research. Oral Dis. 2011, 17, 7-22.
13. Saintigny, P.; Zhang, L.; Fan, Y.-H.; El-Naggar, A.K.; Papadimitrakopoulou, V.A.; Feng, L.; Lee, J.J.; Kim, E.S.; Hong, W.K.; Mao, L. Gene expression profiling predicts the development of oral cancer. Cancer Prev. Res. 2011, 4, 218-229.
14. Kyrgidis, A.; Tzellos, T.G.; Triaridis, S. Melanoma: Stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications. J. Carcinog. 2010, 9, doi: 10.4103/1477-3163.62141.
15. Santos-Rosa, H.; Caldas, C. Chromatin modifier enzymes, the histone code and cancer. Eur. J. Cancer 2005, 41, 2381-2402.
16. Rountree, M.R.; Bachman, K.E.; Herman, J.G.; Baylin, S.B. DNA methylation, chromatin inheritance, and cancer. Oncogene 2001, 20, 3156-3165.
17. Egger, G.; Liang, G.; Aparicio, A.; Jones, P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429, 457-463.
18. Feinberg, A.P.; Ohlsson, R.; Henikoff, S. The epigenetic progenitor origin of human cancer. Nat. Rev. 2006, 7, 21-33.
19. Feinberg, A.P.; Tycko, B. The history of cancer epigenetics. Nat. Rev. Cancer 2004, 4, 143-153.
20. Jones, P.A.; Baylin, S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002, 3, 415-428.
21. Board, R.E.; Knight, L.; Greystoke, A.; Blackhall, F.H.; Hughes, A.; Dive, C.; Ranson, M. DNA methylation in circulating tumour DNA as a biomarker for cancer. Biomark. Insights 2008, 2, 307-319.
22. Bird, A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002, 16, 6-21.
23. Eden, A.; Gaudet, F.; Waghmare, A.; Jaenisch, R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science. 2003, 300, doi:10.1126/science.1083557.
24. Bonazzi, V.F.; Irwin, D.; Hayward, N.K. Identification of candidate tumor suppressor genes inactivated by promoter methylation in melanoma. Genes Chromosom. Cancer 2009, 48, 10-21.
25. Feinberg, A.P.; Cui, H.; Ohlsson, R. DNA methylation and genomic imprinting: Insights from cancer into epigenetic mechanisms. Semin. Cancer Biol. 2002, 12, 389-398.
26. Robertson, K.D. DNA methylation and human disease. Nat. Rev. Genet. 2005, 6, 597-610.
27. Martinez, R.; Martin-Subero, J.I.; Rohde, V.; Kirsch, M.; Alaminos, M.; Fernandez, A.F.; Ropero, S.; Schackert, G.; Esteller, M. A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics 2009, 4, 255-264.
28. Herman, J.G. Hypermethylation of tumor suppressor genes in cancer. Semin. Cancer Biol. 1999, 9, 359-367.
29. Baylin, S.B. DNA methylation and gene silencing in cancer. Nat. Clin. Pract. Oncol. 2005, 2, S4-S11.
30. Shaw, R. The epigenetics of oral cancer. Int. J. Oral. Maxillofac. Surg. 2006, 35, 101-108.
31. Shaw, R.J.; Hall, G.L.; Woolgar, J.A.; Lowe, D.; Rogers, S.N.; Field, J.K.; Liloglou, T.; Risk, J.M. Quantitative methylation analysis of resection margins and lymph nodes in oral squamous cell carcinoma. Br. J. Oral. Maxillofac. Surg. 2007, 45, 617-622.
32. Supić, G.; Kozomara, R.; Branković-Magić, M.; Jović, N.; Magić, Z. Gene hypermethylation in tumor tissue of advanced oral squamous cell carcinoma patients. Oral Oncol. 2009, 45, 1051-1057.
33. Supic, G.; Jovic, N.; Kozomara, R.; Zeljic, K.; Magic, Z. Interaction between the MTHFR C677T polymorphism and alcohol-Impact on oral cancer risk and multiple DNA methylation of tumor-related genes. J. Dent. Res. 2011, 90, 65-70.
34. Radhakrishnan, R.; Kabekkodu, S.; Satyamoorthy, K. DNA hypermethylation as an epigenetic mark for oral cancer diagnosis. J. Oral Pathol. Med. 2011, 40, 665-679.
35. C.Y. Epigenetic alterations in head and neck cancer: Prevalence, clinical significance, and implications. Curr. Oncol. Rep. 2004, 6, 152-161.
36. Shaw, R.J.; Hall, G.L.; Lowe, D.; Liloglou, T.; Field, J.K.; Sloan, P.; Risk, J.M. The role of pyrosequencing in head and neck cancer epigenetics: correlation of quantitative methylation data with gene expression. Arch. Otolaryngol. Head Neck Surg. 2008, 134, 251-256.
37. Glazer, C.A.; Chang, S.S.; Ha, P.K.; Califano, J.A. Applying the molecular biology and epigenetics of head and neck cancer in everyday clinical practice. Oral Oncol. 2009, 45, 440-446.
38. Bennett, K.L.; Hackanson, B.; Smith, L.T.; Morrison, C.D.; Lang, J.C.; Schuller, D.E.; Weber, F.; Eng, C.; Plass, C. Tumor suppressor activity of CCAAT/enhancer binding protein alpha is epigenetically down-regulated in head and neck squamous cell carcinoma. Cancer Res. 2007, 67, 4657-4664.
39. de Freitas Cordeiro-Silva, M.; Oliveira, Z.F.; de Podestá, J.R.; Gouvea, S.A.; von Zeidler, S.V.; Louro, I.D. Methylation analysis of cancer-related genes in non-neoplastic cells from patients with oral squamous cell carcinoma. Mol. Biol. Rep. 2011, 38, 5435-5441.
40. Calmon, M.F.; Rodrigues, R.V.; Kaneto, C.M.; Moura, R.P.; Silva, S.D.; Mota, L.D.; Pinheiro, D.G.; Torres, C.; de Carvalho, A.F.; Cury, P.M.; et al. Epigenetic silencing of CRABP2 and MX1 in head and neck tumors. Neoplasia 2009, 11, 1329-1339.
41. Viswanathan, M.; Tsuchida, N.; Shanmugam, G. Promoter hypermethylation profile oftumorassociated genes p16, p15, hMLH1, MGMT and E-cadherin in oral squamous cell carcinoma. Int. J. Cancer 2003, 105, 41-46.
42. Díez-Pérez, R.; Campo-Trapero, J.; Cano-Sánchez, J.; López-Durán, M.; Gonzalez-Moles, M.A.; Bascones-Ilundain, J.; Bascones-Martinez, A. Methylation in oral cancer and pre-cancerous lesions (Review). Oncol. Rep. 2011, 25, 1203-1209.
43. Kulkarni, V.; Saranath, D. Concurrent hypermethylation of multiple regulatory genes in chewing tobacco associated oral squamous cell carcinomas and adjacent normal tissues. Oral. Oncol. 2004, 40, 145-153.
44. Mancuso, M.; Matassa, D.S.; Conte, M.; Colella, G.; Rana, G.; Fucci, L.; Piscopo, M. H3K4 histone methylation in oral squamous cell carcinoma. Acta Biochim. Pol. 2009, 56, 405-410.
45. Lee, E.S.; Issa, J.P.; Roberts, D.B.; Williams, M.D.; Weber, R.S.; Kies, M.S.; El-Naggar, A.K. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: Comparison with methylation-specific PCR technique and clinical significance. Clin. Cancer Res. 2008, 14, 2664-2672.
46. Kozaki, K.; Imoto, I.; Mogi, S.; Omura, K.; Inazawa, J. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res. 2008, 68, 2094-2105.
47. Kurasawa, Y.; Shiiba, M.; Nakamura, M.; Fushimi, K.; Ishigami, T.; Bukawa, H.; Yokoe, H.; Uzawa, K.; Tanzawa, H. PTEN expression and methylation status in oral squamous cell carcinoma. Oncol. Rep. 2008, 19, 1429-1434.
48. Squarize, C.H.; Castilho, R.M.; Santos Pinto, D., Jr. Immunohistochemical evidence of PTEN in oral squamous cell carcinoma and its correlation with the histological malignancy grading system. J. Oral Pathol. Med. 2002, 31, 379-384.
49. Shin, K.H., Kim, J.M.; Rho, K.S.; Park, K.H., Oh, J.E.; Min, B.M. Inactivation of the PTEN gene by mutation, exonic deletion, and loss of transcript in human oral squamous cell carcinomas. Int. J. Oncol. 2002, 21, 997-1001.
50. Lee, J.I.; Soria, J.C.; Hassan, K.A.; El-Naggar, A.K.; Tang, X.; Liu, D.D.; Hong, W.K.; Mao, L. Loss of PTEN expression as a prognostic marker for tongue cancer. Arch. Otolaryngol. Head Neck Surg. 2001, 127, 1441-1445.
51. Huang, K.H.; Huang, S.F.; Chen, I.H.; Liao, C.T.; Wang, M.; Hsieh, L.L. Methylation of RASSF1A, RASSF2A, and HIN-1 is associated with poor outcome after radiotherapy, but not surgery, in oral squamous cell carcinoma. Clin. Cancer Res. 2009, 15, 4174-4180.
52. Pannone, G.; Bufo, P.; Santoro, A.; Franco, R.; Aquino, G.; Longo, F.; Botti, G.; Serpico, R.; Cafarelli, B.; Abbruzzese, A. et al. WNT pathway in oral cancer: Epigenetic inactivation of WNT-inhibitors. Oncol. Rep. 2010, 24, 1035-1041.
53. Sogabe, Y.; Suzuki, H.; Toyota, M.; Ogi, K.; Imai, T.; Nojima, M.; Sasaki, Y.; Hiratsuka, H.; Tokino, T. Epigenetic inactivation of SFRP genes in oral squamous cell carcinoma. Int. J. Oncol. 2008, 32, 1253-1261.
54. Huang, M.J.; Yeh, K.T.; Shih, H.C.; Wang, Y.F.; Lin, T.H.; Chang, J.Y.; Shih, M.C.; Chang, J.G. The correlation between CpG methylation and protein expression of P16 in oral squamous cell carcinomas. Int. J. Mol. Med. 2002, 10, 551-554.
55. Nakahara, Y.; Shintani, S.; Mihara, M.; Ueyama, Y.; Matsumura, T. High frequency of homozygous deletion and methylation of p16(INK4A) gene in oral squamous cell carcinomas. Cancer Lett. 2001, 163, 221-228.
56. Ogi, K.; Toyota, M.; Ohe-Toyota, M.; Tanaka, N.; Noguchi, M.; Sonoda, T.; Kohama, G.; Tokino, T. Aberrant methylation of multiple genes and clinicopathological features in oral squamous cell carcinoma. Clin. Cancer Res. 2002, 8, 3164-3171.
57. Maruya, S.; Issa, J.P.; Weber, R.S.; Rosenthal, D.I.; Haviland, J.C.; Lotan, R.; El-Naggar, A.K. Differential methylation status of tumor-associated genes in head and neck squamous carcinoma: Incidence and potential implications. Clin. Cancer Res. 2004, 10, 3825-3830.
58. Kato, K.; Hara, A.; Kuno, T.; Mori, H.; Yamashita, T., Toida, M.; Shibata, T. Aberrant promoter hypermethylation of p16 and MGMT genes in oral squamous cell carcinomas and the surrounding normal mucosa. J. Cancer Res. Clin. Oncol. 2006, 132, 735-743.
59. Kresty, L.A.; Mallery, S.R.; Knobloch, T.J.; Song, H.; Lloyd, M.; Casto, B.C.; Weghorst, C.M. Alterations of p16(INK4a) and p14(ARF) in patients with severe oral epithelial dysplasia. Cancer Res. 2002, 62, 5295-5300.
60. Takeshima, M.; Saitoh, M.; Kusano, K.; Nagayasu, H.; Kurashige, Y.; Malsantha, M.; Arakawa, T.; Takuma, T.; Chiba, I.; Kaku, T. et al. High frequency of hypermethylation of p14, p15 and p16 in oral pre-cancerous lesions associated with betel-quid chewing in Sri Lanka. J. Oral Pathol. Med. 2008, 37, 475-479.
61. Saito, Y.; Takazawa, H.; Uzawa, K.; Tanzawa, H.; Sato, K. Reduced expression of E-cadherin in oral squamous cell carcinoma: Relationship with DNA methylation of 5′ CpG island. Int. J. Oncol. 1998, 12, 293-298.
62. Nakayama, S.; Sasaki, A.; Mese, H.; Alcalde, R.E.; Tsuji, T.; Matsumura, T. The E-cadherin gene is silenced by CpG methylation in human oral squamous cell carcinomas. Int. J. Cancer 2001, 93, 667-673.
63. Chang, H.W.; Chow, V.; Lam, K.Y.; Wei, W.I.; Yuen, A. Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance. Cancer 2002, 94, 386-392.
64. Hasegawa, M.; Nelson, H.H.; Peters, E.; Ringstrom, E.; Posner, M.; Kelsey, K.T. Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene. 2002, 21, 4231-4236.
65. Viet, C.T.; Jordan, R.C.; Schmidt, B.L. DNA promoter hypermethylation in saliva for the early diagnosis of oral cancer. J. Calif. Dent. Assoc. 2007, 35, 844-849.
66. Vered, M.; Allon, I.; Buchner, A.; Dayan, D. E-cadherin in oral SCC: An analysis of the confusing literature and new insights related to its immunohistochemical expression. Histol. Histopathol. 2012, 27, 141-150.
67. Di Domenico, M.; Pierantoni, G.M.; Feola, A.; Esposito, F.; Laino, L.; de Rosa, A.; Rullo, R.; Mazzotta, M.; Martano, M.; Sanguedolce, F. et al. Prognostic significance of N-cadherin expression in oral squamous cell carcinoma. Anticancer Res. 2011, 12, 4211-4218.
68. Renner, O.; Blanco-Aparicio, C.; Carnero, A. Genetic modelling of the PTEN/AKT pathway in cancer research. Clin. Transl. Oncol. 2008, 10, 618-627.
69. Zhu, Y.; Wloch, A.; Wu, Q.; Peters, C.; Pagenstecher, A.; Bertalanffy, H.; Sure, U. Involvement of PTEN promoter methylation in cerebral cavernous malformations. Stroke 2009, 40, 820-826.
70. Salvesen, H.B.; MacDonald, N.; Ryan, A.; Jacobs, I.J.; Lynch, E.D.; Akslen, L.A.; Das, S. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int. J. Cancer 2001, 91, 22-26.
71. Kang, Y.H.; Lee, H.S.; Kim, W.H. Promoter methylation and silencing of PTEN in gastric carcinoma. Lab. Invest. 2002, 82, 285-291.
72. Soria, J.C.; Lee, H.Y.; Lee, J.I.; Wang, L.; Issa, J.P.; Kemp, B.L.; Liu, D.D.; Kurie, J.M.; Mao, L.; Khuri, F.R. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin. Cancer Res. 2002, 8, 1178-1184.
73. Yang, H.J.; Liu, V.W.; Wang, Y.; Tsang, P.C.; Ngan, H.Y. Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer 2006, 6, doi:10.1186/1471-2407-6-212.
74. Chen, Q.; Samaranayake, L.P.; Zhou, H.; Xiao, L. Homozygous deletion of the PTEN tumor-suppressor gene is not a feature in oral squamous cell carcinoma. Oral Oncol. 2000, 36, 95-99.
75. Mavros, A.; Hahn, M.; Wieland, I.; Koy, S.; Koufaki, O.N.; Strelocke, K.; Koch, R.; Haroske, G.; Schackert, H.K.; Eckelt, U. Infrequent genetic alterations of the tumor suppressor gene PTEN/MMAC1 in squamous cell carcinoma of the oral cavity. J. Oral Pathol. Med. 2002, 31, 270-276.
76. Koch, R.; Haroske, G.; Schackert, H.K.; Eckelt, U. Infrequent genetic alterations of the tumor suppressor gene PTEN/MMAC1 in squamous cell carcinoma of the oral cavity. J. Oral Pathol. Med. 2002, 31, 270-276.
77. Levine, A.J.; Momand, J.; Finlay, C.A. The p53 tumour suppressor gene. Nature 1991, 351, 453-456.
78. Boyle, J.O.; Hakim, J.; Koch, W., van der Riet, P.; Hruban, R.H.; Roa, R.A.; Correo, R.; Eby, Y.J.; Ruppert, J.M.; Sidransky, D. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res. 1993, 53, 4477-4480.
79. Caamano, J.; Zhang, S.Y.; Rosvold, E.A.; Bauer, B.; Klein-Szanto, A.J. p53 alterations in human squamous cell carcinomas and carcinoma cell lines. Am. J. Pathol. 1993, 142, 1131-1139.
80. Baral, R.; Patnaik, S.; Das B.R. Co-overexpression of p53 and c-myc proteins linked with advanced stages of betel- and tobacco-related oral squamous cell carcinomas from eastern India. Eur. J. Oral Sci. 1998, 106, 907-913.
81. Ha, P.K.; Califano, J.A. Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol. 2006, 7, 77-82.
82. Sanchez-Cespedes, M.; Esteller, M.; Wu, L.; Nawroz-Danish, H.; Yoo, G.H.; Koch, W.M.; Jen, J.; Herman, J.G.; Sidransky, D. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res. 2000, 60, 892-895.
83. Rosas, S.L.; Koch, W.; da Costa Carvalho, M.G.; Wu, L.; Califano, J.; Westra, W.; Jen, J.; Sidransky, D. Promoter hypermethylation patterns of p16, O6-methylguanine-DNAmethyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res. 2001, 61, 939-942.
84. Roth, M.J.; Abnet, C.C.; Hu, N.; Wang, Q.H.; Wie, W.Q.; Green, L.; D'Alelio, M.; Qiao, Y.L.; Dawsey, S.M.; Taylor, P.R.; Woodson, K. p16, MGMT, RARbeta2, CLDN3, CRBP and MT1G gene methylation in esophageal squamous cell carcinoma and its precursor lesions. Oncol. Rep. 2006, 15, 1591-1597.
85. Sawhney, M.; Rohatgi, N.; Kaur, J.; Gupta, S.D.; Deo, S.V.; Shukla, N.K.; Ralhan, R. MGMT expression in oral precancerous and cancerous lesions: Correlation with progression, nodal metastasis and poor prognosis. Oral Oncol. 2007, 43, 515-522.
86. Youssef, E.M.; Lotan, D.; Issa, J.; Wakasa, K.; Fan, Y.H.; Mao, L.; Hassan, K.; Feng, L.; Lee, J.J.; Lippman, S.M. et al. Hypermethylation of the retinoic acid receptor-β(2) gene in head and neck carcinogenesis. Clin. Cancer Res. 2004, 10, 1733-1742.
87. Imai, T.; Toyota, M.; Suzuki, H.; Akino, K.; Ogi, K.; Sogabe, Y.; Kashima, L.; Maruyama, R.; Nojima, M.; Mita, H. et al. Epigenetic inactivation of RASSF2 in oral squamous cell carcinoma. Cancer Sci. 2008, 99, 958-966.
88. Sigalotti, L.; Covre, A.; Fratta, E.; Parisi, G.; Colizzi, F.; Rizzo, A.; Danielli, R.; Nicolay, H.J.; Coral, S.; Maio, M. Epigenetics of human cutaneous melanoma: Setting the 66 research on Melanoma: A glimpse into current directions and future trends stage for new therapeutic strategies. J. Transl. Med. 2010, 8, 56.
89. Guil, S.; Esteller, M. DNA methylomes, histone codes and miRNAs: Tying it all together. Int. J. Biochem. Cell Biol. 2009, 41, 87-95.
90. Calin, G.A.; Croce, C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6, 857-866.
91. Sood, P.; Krek, A.; Zavolan, M.; Macino, G.; Rajewsky, N. Cell-type-specific signatures of microRNAs on target mRNA expression. Proc. Natl. Acad. Sci. USA 2006, 103, 2746-2751.
92. Lujambio, A.; Ropero, S.; Ballestar, E.; Fraga, M.F.; Cerrato, C.; Setién, F.; Casado, S.; Suarez-Gauthier, A.; Sanchez-Cespedes, M.; Git A. et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res. 2007, 67, 1424-1429.
93. Saito, Y.; Liang, G.; Egger, G.; Friedman, J.M.; Chuang, J.C.; Coetzee, G.A.; Jones, P.A. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006, 9, 435-443.
94. Cervigne, N.K.; Reis, P.P.; Machado, J.; Sadikovic, B.; Bradley, G.; Galloni, N.N.; Pintilie, M.; Jurisica, I.; Perez-Ordonez, B.; Gilbert, R. et al. Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma. Hum. Mol. Genet. 2009, 18, 4818-4829.
95. Wong, T.S.; Liu, X.B.; Chung-Wai Ho, A.; Po-Wing Yuen, A.; Wai-Man Ng, R.; Ignace Wei, W. Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling. Int. J. Cancer 2008, 123, 251-257.
96. Olive, V.; Jiang, I., He, L. mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int. J. Biochem. Cell Biol. 2010, 42, 1348-1354.
97. Jevnaker, A.M.; Khuu, C.; Kjøle, E.; Bryne, M.; Osmundsen, H. Expression of members of the miRNA17-92 cluster during development and in carcinogenesis. J. Cell. Physiol. 2011, 226, 2257-2266.
98. Hu, W.; Chan, C.S.; Wu, R.; Zhang, C.; Sun, Y.; Song, J.S.; Tang, L.H.; Levine, A.J.; Feng, Z. Negative regulation of tumor suppressor p53 by microRNA miR-504. Mol. Cell 2010, 38, 689-699.
99. Wu, B.H.; Xiong, X.P.; Jia, J.; Zhang, W.F. MicroRNAs: New actors in the oral cancer scene. Oral Oncol. 2011, 47, 314-319.
100. Gorenchtein, M.; Poh, C.F.; Saini, R.; Garnis, C. MicroRNAs in an oral cancer context-From basic biology to clinical utility. J. Dent. Res. 2011, doi:10.1177/0022034511431261.
101. Jenuwein, T.; Allis, C.D. Translating the histone code. Science 2001, 293, 1074-1080.
102. Strahl, B.D.; Allis, C.D. The language of covalent histone modifications. Nature 2000, 403, 41-45.
103. Ramirez-Parra, E.; Gutierrez, C. The many faces of chromatin assembly factor 1. Trends Plant Sci. 2007, 12, 570-576.
104. Ridgway, P.; Almouzni, G. CAF-1 and the inheritance of chromatin states: At the crossroads of DNA replication and repair. J. Cell Sci. 2000, 113, 2647-2658.
105. Das, C.; Lucia, M.S.; Hansen, K.C.; Tyler, J.K. CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature 2009, 459, 113-117.
106. Li, Q.; Huang, Y.; Xiao, N.; Murray, V.; Chen, J.; Wang, J. Real time investigation of protein folding, structure, and dynamics in living cells. Methods Cell Biol. 2008, 90, 287-325.
107. Chen, C.C.; Tyler, J. Chromatin reassembly signals the end of DNA repair. Cell Cycle 2008, 7, 3792-3797.
108. Kadyrova, L.Y.; Blanko, E.R.; Kadyrov, F.A. CAF-I-dependent control of degradation of the discontinuous strands during mismatch repair. Proc. Natl. Acad. Sci. USA 2011, 108, 2753-2758.
109. Kim, J.A.; Haber, J.E. Chromatin assembly factors Asf1 and CAF-1 have overlapping roles in deactivating the DNA damage checkpoint when DNA repair is complete. Proc. Natl. Acad. Sci. USA 2009, 106, 1151-1156.
110. Henikoff, S. Versatile assembler. Nature 2003, 423, 814-817.
111. Polo, S.E.; Theocharis, S.E.; Klijanienko, J.; Savignoni, A.; Asselain, B.; Vielh, P.; Almouzni, G. Chromatin Assembly Factor-1, a marker of clinical value to distinguish quiescent from proliferating cells. Cancer Res. 2004, 64, 2371-2381.
112. Ye, X.; Franco, A.A.; Santos, H.; Nelson, D.M.; Kaufmann, P.D.; Adams, P.D. Defective S phase chromatin assembly causes DNA damage, activation of the S phase checkpoint, and S phase arrest. Mol. Cell 2003, 11, 341-351.
113. Gaillard, P.H.; Martini, E.M.; Kaufman, P.D.; Stillman, B.; Moustacchi, E.; Almouzni, G. Chromatin assembly coupled to DNA repair: A new role for chromatin assembly factor I. Cell 1996, 86, 887-896.
114. Techenio, T.; Casella, J.F.; Heidmann, T. A truncated form of human CAF-1 p150 subunits impairs the maintenance of transcriptional gene silencing in mammalian cells. Mol. Cell. Biol. 2001, 21, 953-961.
115. Staibano, S.; Mascolo, M.; Mancini, F.P.; Kisslinger, A.; Salvatore, G.; Di Benedetto, M.; Chieffi, P.; Altieri, V.; Prezioso, D.; Ilardi, G.; et al. Overexpression of chromatin assembly factor-1 (CAF-1) p60 is predictive of adverse behaviour of prostatic cancer. Histopathology 2009, 54, 580-589.
116. Mascolo, M.; Vecchione, M.L.; Ilardi, G.; Scalvenzi, M.; Molea, G.; Di Benedetto, M.; Nugnes, L.; Siano, M.; de Rosa, G.; Staibano, S. Overexpression of Chromatin Assembly Factor-1/p60 helps to predict the prognosis of melanoma patients. BMC Cancer 2010, 24, doi: 10.1186/1471-2407-10-63.
117. Staibano, S.; Mascolo, M.; Rocco, A.; Lo Muzio, L.; Ilardi, G.; Siano, M.; Pannone, G.; Vecchione, M.L.; Nugnes, L.; Califano, L. et al. The proliferation marker Chromatin Assembly Factor-1 is of clinical value in predicting the biological behaviour of salivary gland tumours. Oncol. Rep. 2011, 25, 13-22.
118. Staibano, S.; Mignogna, C.; Lo Muzio, L.; Mascolo, M.; Salvatore, G.; Di Benedetto, M.; Califano, L.; Rubini, C.; de Rosa, G. Chromatin assembly factor-1 (CAF-1)-mediated regulation of cell proliferation and DNA repair: A link with the biological behaviour of squamous cell carcinoma of the tongue? Histopathology 2007, 50, 911-919.
119. Polo, S.E.; Theocharis, S.E.; Grandin, L.; Gambotti, L.; Antoni, G.; Savignoni, A.; Asselain, B.; Patsouris, E.; Almouzni, G. Clinical significance and prognostic value of chromatin assembly factor-1 overexpression in human solid tumours. Histopathology 2010, 57, 716-724.
120. Sakuma, T.; Uzawa, K.; Onda, T.; Shiiba, M.; Yokoe, H.; Shibahara, T.; Tanzawa, H. Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int. J. Oncol. 2006, 29, 117-124.
121. Sato, T.; Suzuki, M.; Sato, Y.; Echigo, S.; Rikiishi, H. Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells. Int. J. Oncol. 2006, 28, 1233-1241.
122. Rikiishi, H.; Shinohara, F.; Sato, T.; Sato, Y.; Suzuki, M.; Echigo, S. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid. Int. J. Oncol. 2007, 30, 1181-1188.
123. Chang, H.H.; Chiang, C.P.; Hung, H.C.; Lin, C.Y.; Deng, Y.T.; Kuo, M.Y. Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. Oral Oncol. 2009, 45, 610-614.
124. Chung, Y.L.; Lee, M.Y.; Pui, N.N. Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: Prevention of radiationinduced oral mucositis and inhibition of chemical-induced oral carcinogenesis. Carcinogenesis 2009, 30, 1387-1397.
125. Shen, J.; Huang, C.; Jiang, L.; Gao, F.; Wang, Z.; Zhang, Y.; Bay, J.; Zhou, H.; Chen, Q. Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines. Biochem. Pharmacol. 2007, 73, 1901-1909.
126. Murakami, J.; Asaumi, J.; Maki, Y.; Tsujigiwa, H.; Kuroda, M.; Nagai, N.; Yanagi, Y.; Inoue, T.; Kawasaki, S.; Tanaka, N. et al. Effects of demethylating agent 5-aza-2(0)-deoxycytidine and histone deacetylase inhibitor FR901228 on maspin gene expression in oral cancer cell lines. Oral Oncol. 2004, 40, 597-603.
127. Murakami, J.; Asaumi, J.; Kawai, N.; Tsujigiwa, H.; Yanagi, Y.; Nagatsuka, H.; Inoue, T.; Kokeguchi, S.; Kawasaki, S.; Kuroda, M. et al. Effects of histone deacetylase inhibitor FR901228 on the expression level of telomerase reverse transcriptase in oral cancer. Cancer Chemother. Pharmacol. 2005, 56, 22-28.
128. D'Souza, G.; Kreimer, A.R.; Viscidi, R.; Pawlita, M.; Fakhry, C.; Koch, W.M.; Westra, W.H.; Gillison, M.L. Case-control study of human papillomavirus and oropharyngeal cancer. N. Engl. J. Med. 2007, 356, 1944-1956.
129. Adelstein, D.J.; Rodriguez, C.P. Human papillomavirus: Changing paradigms in oropharyngeal cancer. Curr. Oncol. Rep. 2010, 12, 115-120.
130. Stock, M.L.; Peterson, L.M.; Houlihan, A.E.; Walsh, L.A. Influence of oral sex and oral cancer information on young adults' oral sexual-risk cognitions and likelihood of hpv vaccination. J. Sex Res. 2012, doi: 10.1111/j.1365-263X.2011.01219.x.
131. Murugan, A.K.; Munirajan, A.K.; Tsuchida, N. Ras oncogenes in oral cancer: The past 20 years. Oral Oncol. 2012, doi: 10.1016/j.oraloncology.2011.12.006.
132. Sanders, A.; Slade, G.; Patton, L. National prevalence of oral HPV infection and related risk factors in the US adult population. Oral Dis. 2011, doi: 10.1111/j.1601-0825.2011.01892.x.
133. Miller, C.S.; Johnstone, B.M. Human papillomavirus as a risk factor for oral squamous cell carcinoma: A meta- analysis, 1982-1997. Oral Surg. Oral Med. Oral. Pathol. Oral Radiol. Endod. 2001, 91, 622-635.
134. Syrjanen, S.; Syrjanen, K. HPV Infections of the Oral Mucosa. In Papillomavirus Infections in Human Pathology; Syrjanen, K., Syrjanen, S., Eds.; John Wiley & Sons: New York, NY, USA, 2000; Chapter 17, pp. 379-412.
135. Syrjänen, S.; Lodi, G.; von Bültzingslöwen, I.; Aliko, A.; Arduino, P.; Campisi, G.; Challacombe, S.; Ficarra, G.; Flaitz, C.; Zhou, H.M. et al. Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: A systematic review. Oral Dis. 2011, 17, 58-72.
136. Termine, N.; Panzarella, V.; Falaschini, S.; Russo, A., Matranga, D.; Lo Muzio, L.; Campisi, G. HPV in oral squamous cell carcinoma vs. head and neck squamous cell carcinoma biopsies: A meta-analysis (1988-2007). Ann. Oncol. 2008, 10, 1681-1690.
137. Kreimer, A.R.; Clifford, G.M.; Boyle, P.; Franceschi, S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: A systematic review. Cancer Epidemiol. Biomark. Prev. 2005, 14, 467-475.
138. Smith, E.M.; Ritchie, J.M.; Yankowitz, J.; Swarnavel, S.; Wang, D.; Haugen, T.H.; Turek, L.P. Human papillomavirus prevalence and types in newborns and parents: Concordance and modes of transmission. Sex Transm. Dis. 2004, 1, 57-62.
139. Dayyani, F.; Etzel, C.J.; Liu, M.; Ho, C.H.; Lippman, S.M.; Tsao, A.S. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol. 2010, 2, doi:10.1186/1758-3284-2-15.
140. Zhao, D.; Xu, Q.G.; Chen, X.M.; Fan, M.W. Human papillomavirus as an independent predictor in oral squamous cell cancer. Int. J. Oral Sci. 2009, 1, 119-125.
141. Shi, W.; Kato, H.; Perez-Ordonez, B.; Pintilie, M.; Huang, S.; Hui, A.; O'Sullivan, B.; Waldron, J.; Cummings, B.; Kim, J. et al. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J. Clin. Oncol. 2009, 27, 6213-6221.
142. Wiest, T.; Schwarz, E.; Enders, C.; Flechtenmacher, C.; Bosch, F.X. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 2002, 21, 1510-1517.
143. Boyer, S.N.; Wazer, D.E.; Band, V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 1996, 56, 4620-4624.
144. Snow, A.; Laudadio, J. Human papillomavirus detection in head and neck squamous cell carcinomas. Adv. Anat. Pathol. 2010, 17, 394-403.
145. Smeets, S.J.; Hesselink, A.T.; Speel, E.J.; Haesevoets, A.; Snijders, P.J.; Pawlita, M.; Meijer, C.J.; Braakhuis, B.J.; Leemans, C.R.; Brakenhoff, R.H. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int. J. Cancer 2007, 121, 2465-2472.
146. Patel, D.; Huang, S.M.; Baglia, L.A.; McCance, D.J. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J. 1999, 18, 5061-5072.
147. Longworth, M.S.; Laimins, L.A. The binding of histone deacetylases and the integrity of zinc finger-like motifs of the E7 protein are essential for the life cycle of human papillomavirus type 31. J. Virol. 2004, 78, 3533-3541.
148. Lin, T.S.; Lee, H.; Chen, R.A.; Ho, M.L.; Lin, C.Y.; Chen, Y.H.; Tsai, Y.Y.; Chou, M.C.; Cheng, Y.W. An association of DNMT3b protein expression with P16INK4a promoter hypermethylation in non-smoking female lung cancer with human papillomavirus infection. Cancer Lett. 2005, 226, 77-84.
149. Burgers, W.A.; Blanchon, L.; Pradhan, S.; de Launoit, Y.; Kouzarides, T.; Fuks, F. Viral oncoproteins target the DNA methyltransferases. Oncogene 2007, 26, 1650-1655.
150. Gore, D.S. Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies. Nat. Clin. Pract. Oncol. 2005, 2, S30-S35.
151. Quintás-Cardama, A.; Santos, F.P.; Garcia-Manero, G. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia. 2011, 25, 226-235.
152. Momparler, R.L.; Ayoub, J. Potential of 5-aza-2'-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. Lung Cancer 2001, 34, S111-S115.
153. Coombes, M.M.; Briggs, K.L.; Bone, J.R.; Clayman, G.L.; El-Naggar, A.K.; Dent, S.Y. Resetting the histone code at CDKN2A in HNSCC by inhibition of DNA methylation. Oncogene 2003, 22, 8902-8911.
154. ClinicalTrials Home Page. Available online: http://www.clinicaltrials.gov (accessed on 21 February 2012).
155. Balch, C.; Yan, P.; Craft, T.; Young, S.; Skalnik, D.G.; Huang, T.H.; Nephew, K.P. Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol. Cancer Ther. 2005, 4, 1505-1514.
156. Suzuki, M.; Shinohara, F.; Nishimura, K.; Echigo, S.; Rikiishi, H. Epigenetic regulation of chemosensitivity to 5-fluorouracil and cisplatin by zebularine in oral squamous cell carcinoma. Int. J. Oncol. 2007, 31, 1449-1456.